Current Environment: Production

Summary

Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. The molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described. The goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (CHD) to better understand mechanisms responsible for abnormal clotting in the perioperative period.

Conditions

Congenital Heart Disease, Single-ventricle, Thrombosis

Recruitment Status

RECRUITING

Eligibility Criteria

Inclusion Criteria:

* All neonates with a diagnosis of severe Congenital Heart Disease undergoing surgery at Boston Children's Hospital in the first week of life

Exclusion Criteria:

* None

Intervention

Intervention Type

Intervention Name

OTHER

Collecting discarded blood samples

Gender

ALL

Min Age

1 Day

Max Age

7 Days

Download Date

2024-10-29

Principal Investigator

N/A

Primary Contact Information

Rachel Bernier, MPH
rachel.bernier@childrens.harvard.edu

Hanna Van Pelt, BS
hanna.vanpelt@childrens.harvard.edu

This field has been modified from ClinicalTrials.gov to show a contact specific to Boston Children's.

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis NCT06434207 Rachel Bernier, MPH rachel.bernier@childrens.harvard.edu Hanna Van Pelt, BS hanna.vanpelt@childrens.harvard.edu